Latest Insider Transactions at Ani Pharmaceuticals Inc (ANIP)
This section provides a real-time view of insider transactions for Ani Pharmaceuticals Inc (ANIP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ANI PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ANI PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 23
2022
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,167
-3.7%
|
$112,509
$27.03 P/Share
|
|
Mar 23
2022
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
2,452
-2.14%
|
$66,204
$27.03 P/Share
|
|
Mar 21
2022
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
7,224
+4.08%
|
$195,048
$27.69 P/Share
|
|
Mar 21
2022
|
Patrick D Walsh Director |
BUY
Open market or private purchase
|
Direct |
5,000
+8.56%
|
$135,000
$27.76 P/Share
|
|
Mar 21
2022
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
BUY
Open market or private purchase
|
Indirect |
5,000
+1.26%
|
$135,000
$27.87 P/Share
|
|
Mar 19
2022
|
Renee P Tannenbaum Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,346
+50.0%
|
-
|
|
Mar 18
2022
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
BUY
Open market or private purchase
|
Indirect |
5,000
+1.27%
|
$135,000
$27.15 P/Share
|
|
Mar 17
2022
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Open market or private purchase
|
Indirect |
5,000
+50.0%
|
$135,000
$27.65 P/Share
|
|
Mar 17
2022
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Open market or private purchase
|
Direct |
5,000
+21.31%
|
$135,000
$27.65 P/Share
|
|
Feb 15
2022
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,167
-9.04%
|
$46,680
$40.25 P/Share
|
|
Feb 15
2022
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,184
-7.34%
|
$47,360
$40.25 P/Share
|
|
Dec 20
2021
|
Jeanne Thoma Director |
BUY
Open market or private purchase
|
Direct |
1,072
+5.68%
|
$49,312
$46.47 P/Share
|
|
Dec 07
2021
|
Antonio R Pera Director |
BUY
Open market or private purchase
|
Direct |
3,000
+13.21%
|
$126,000
$42.26 P/Share
|
|
Dec 06
2021
|
Thomas Haughey Director |
BUY
Open market or private purchase
|
Direct |
2,500
+7.64%
|
$97,500
$39.38 P/Share
|
|
Nov 19
2021
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
BUY
Grant, award, or other acquisition
|
Indirect |
383,226
+50.0%
|
-
|
|
Nov 19
2021
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Grant, award, or other acquisition
|
Indirect |
1,332,620
+50.0%
|
-
|
|
Nov 19
2021
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Grant, award, or other acquisition
|
Direct |
13,460
+50.0%
|
-
|
|
Sep 08
2021
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,577
-1.56%
|
$72,156
$28.2 P/Share
|
|
Apr 12
2021
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,042
-2.63%
|
$94,302
$31.86 P/Share
|
|
Apr 12
2021
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
1,878
-1.62%
|
$58,218
$31.86 P/Share
|
|
Apr 06
2021
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
612
-0.53%
|
$20,196
$33.69 P/Share
|
|
Apr 06
2021
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
337
-0.29%
|
$11,121
$33.69 P/Share
|
|
Mar 31
2021
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
508
-0.44%
|
$18,288
$36.14 P/Share
|
|
Mar 31
2021
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
278
-0.24%
|
$10,008
$36.14 P/Share
|
|
Mar 29
2021
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
953
-0.81%
|
$30,496
$32.68 P/Share
|
|
Mar 29
2021
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
524
-0.45%
|
$16,768
$32.68 P/Share
|
|
Mar 29
2021
|
Robert W Schrepfer SVP - NEW BUS DEV & SPEC SALES |
SELL
Payment of exercise price or tax liability
|
Direct |
5,566
-5.98%
|
$178,112
$32.68 P/Share
|
|
Mar 23
2021
|
Patrick D Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,292
+16.11%
|
-
|
|
Mar 23
2021
|
Robert E. Brown Jr |
BUY
Grant, award, or other acquisition
|
Direct |
9,292
+19.25%
|
-
|
|
Mar 23
2021
|
Thomas Haughey Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,292
+25.12%
|
-
|
|
Mar 23
2021
|
David Nash Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,292
+30.03%
|
-
|
|
Mar 23
2021
|
Jeanne Thoma Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,292
+35.73%
|
-
|
|
Mar 23
2021
|
Antonio R Pera Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,292
+35.73%
|
-
|
|
Mar 23
2021
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
136,495
+45.27%
|
-
|
|
Mar 23
2021
|
Stephen P. Carey SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
54,470
+31.65%
|
-
|
|
Mar 23
2021
|
James G. Marken SVP OPS & PROD DEV |
BUY
Grant, award, or other acquisition
|
Direct |
32,041
+21.45%
|
-
|
|
Mar 15
2021
|
Patrick D Walsh Director |
BUY
Open market or private purchase
|
Direct |
4,000
+9.28%
|
$128,000
$32.89 P/Share
|
|
Feb 15
2021
|
Ori Gutwerg SVP, GENERICS |
BUY
Grant, award, or other acquisition
|
Direct |
12,907
+50.0%
|
-
|
|
Feb 15
2021
|
Christopher Mutz HEAD OF RARE DISEASE |
BUY
Grant, award, or other acquisition
|
Direct |
16,134
+50.0%
|
-
|
|
Nov 09
2020
|
Patrick D Walsh Director |
BUY
Open market or private purchase
|
Direct |
5,000
+12.47%
|
$125,000
$25.96 P/Share
|